艾斯特伯利什实验室 ESTA

Filippo Peter Caldini served as our President from August 2024 through February 2025 and has served as our Chief Executive Officer since March 2025. Previously, Mr. Caldini was Chief Executive Officer at and a director of Acreage Holdings, Inc., a publicly traded cannabis and medical marijuana company, from December 2020 to June 2023, and Chief Executive Officer and a director of Bespoke Capital Acquisition Corp., a special purpose acquisition corporation, from June 2019 until December 2020. He also held positions at Pfizer Consumer Healthcare, a consumer healthcare business, as Regional President North America from 2017 to 2019, Regional President EMEA from 2016 to 2017, and led the Northern European cluster from 2015 to 2016. From 2009 to 2014, he also served in several leadership roles at Bayer AG, a global enterprise with core competencies in the life science fields of healthcare and agriculture. Mr. Caldini received a Masters of International Economics and Management from Bocconi University in Milan, Italy, an M.B.A. from Northeastern University and a B.A., Political Science from Boston University.

Rajbir S. Denhoy served as our Chief Financial Officer from December 2021 to March 2026 and previously served as our Interim Chief Financial Officer from August 2021 to December 2021. Prior to such time, Mr. Denhoy served as our Head of Strategy and Investor Relations from February 2021 to December 2021. Prior to joining the Company in February 2021, Mr. Denhoy served as a Managing Director of the Jefferies Group, LLC, investment banking and financial services firm, from December 2009 until February 2021. Mr. Denhoy holds a bachelor's degree in biology from UC Berkeley, a master's degree in physiology from Georgetown University, and an M.B.A. from Cornell University. Mr. Denhoy continues to serve the Company as Senior Vice President, Global Strategy.

Mr. Lewin has served on our Board since September 2015, and as Chairman since December 2017. He has been a private investor since 2000 and has invested across multiple industries, with a particular focus on companies with innovative technologies and strong intellectual property, including activist situations that require working with management. Mr. Lewin has been a director of Allurion Technologies, Inc., a medical technology company, since October 2023. Previously, Mr. Lewin served as a director of GameSquare Holdings, Inc. (including its predecessor, FaZe Holdings, Inc.) from July 2022 to December 2025 and Cutera, Inc., a global medical technology company, from May 2023 to March 2025. Mr. Lewin holds a bachelor's degree in Political Science from Johns Hopkins University. We believe Mr. Lewin is qualified to serve on our Board due to his experience as an investor in, and director of, innovative companies, including healthcare companies.

S. Ross Mansbach has served as our General Counsel and Chief Compliance Officer since August 2022, and he also served as our Chief Human Resources Officer from April 2023 until August 2024. Mr. Mansbach previously was at Avanos Medical, Inc., a publicly traded medical device company, where between November 2014 and March 2022 he held positions including Senior Vice President, Interim General Counsel and Corporate Secretary and Vice President, Deputy General Counsel and Corporate Secretary. Prior to such time, he held roles in the Legal Department at Kimberly-Clark Corporation for over 10 years. Mr. Mansbach was also formerly a partner at the law firm Powell Goldstein Frazer & Murphy, now known as Bryan Cave Leighton Paisner LLP. Mr. Mansbach received a B.A. from Yale College and a J.D. from the University of Chicago.

Ms. Custin has served on our Board since July 2020. She served as Chief Financial Officer and on the board of directors of Siemens Medical Solutions Inc., a global medical technology company, from February 2012 to December 2019. Ms. Custin previously served as Chief Operating and Financial Officer of Scient'x S.A.S., a medical device company, and President and CEO USA of Draeger Medical Systems, Inc., a medical and safety technology company, from 2004 to 2008. She has served on the board of directors of Mayne Pharma Group Limited, a specialty pharmaceutical company, since March 2022 and Volpara Health Technologies Limited, a medical technology company, from September 2021 to May 2024. Ms. Custin holds a B.A. in Accounting from Queens College, CUNY. We believe Ms. Custin is qualified to serve on our Board due to her extensive career in healthcare across Europe, the Americas, and Asia.

On June 24, 2026, the Board of Directors of Establishment Labs Holdings Inc. appointed Taylor Harris to the Board, effective immediately, to serve until the Company's 2027 annual meeting of shareholders and until his successor is duly elected and qualified. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He currently serves on the board of directors of Procept BioRobotics and previously served as a director of Omada Health and Endologix. Most recently, he served as Chief Executive Officer of Cutera, Inc. Prior to Cutera, Mr. Harris served as Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. Earlier in his career, he served as Chief Financial Officer of Zeltiq Aesthetics through its acquisition by Allergan and as Chief Financial Officer of Thoratec Corporation through its acquisition by St. Jude Medical. He also spent more than a decade at JPMorgan Chase & Co. in healthcare equity research and investment banking roles.

Cassandra Sandra Harris was appointed Senior Vice President and Chief Financial Officer effective March 9, 2026. She brings extensive global finance and operational leadership experience, including prior service as Chief Financial Officer of Genesco Inc., a retailer, wholesale distributor and manufacturer, from 2024 to 2026, and Artisan Design Group, LLC, a national provider of interior finishes, from 2023 to 2024, as well as Chief Financial Officer and Chief Operating Officer of Tupperware Brands Corporation, a global consumer products company, from 2019 to 2022 and 2020 to 2022, respectively. Earlier in her career, she held senior finance and operational roles at VF Corporation, an apparel and footwear company, and began her career in audit at Deloitte & Touche LLP, a professional services firm. Ms. Harris is a Certified Public Accountant and holds a Bachelor of Science in Accounting from Clemson University.